Enclomiphene Benefits: What Studies Report

How this page frames "benefits"

Enclomiphene citrate is the trans-isomer of clomiphene citrate and has been characterised in the literature as an estrogen receptor antagonist investigated for testosterone deficiency in men (PMID 19204885). The word "benefit" does not appear in trial protocols; what appears instead is a list of measured endpoints — hormone concentrations, semen parameters, symptom questionnaires, adverse events. This page organises the published findings by outcome domain and states, for each, what kind of study produced the result, in whom, and in which direction the effect was reported. Where an outcome people ask about has not been well studied, that is stated plainly rather than filled in with inference.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning hormones, fertility or medication.

Outcome domains at a glance

Hormonal outcomes: testosterone, LH and FSH

The most consistently measured endpoint across the enclomiphene literature is serum testosterone. A 2013 pharmacodynamic and pharmacokinetic study in men with secondary hypogonadism examined daily oral doses of 12.5 mg and 25 mg of enclomiphene citrate and reported restoration of testosterone concentrations alongside changes in gonadotropins (PMID 23875626). A separate 2013 study in men with low testosterone reported that oral enclomiphene citrate stimulated endogenous testosterone production and sperm counts, with testosterone gel used as the comparator (PMID 23530575).

Researchers have described the mechanism as central rather than gonadal: by antagonising estrogen receptors in the hypothalamic–pituitary axis, the compound was reported to increase luteinising hormone and follicle-stimulating hormone output, which in turn drove testicular testosterone production in men with an intact testicular response (PMID 27337642). The same framing — an estrogen receptor antagonist developed for testosterone deficiency — appears in an earlier drug-profile review (PMID 19204885). That mechanism matters for interpreting the literature: the studied population was men whose deficiency originated above the testis, not men with primary testicular failure.

Comparison with topical testosterone

Two of the better-known comparisons set enclomiphene against exogenous testosterone rather than against placebo alone. The 2013 comparison study reported endogenous testosterone stimulation with enclomiphene in contrast to testosterone gel (PMID 23530575), and a 2014 randomised phase II trial comparing topical testosterone reported that enclomiphene citrate stimulated testosterone production while preventing oligospermia (PMID 25044085); that trial evaluated 12.5 mg and 25 mg daily oral dosing. The directional claim in these reports was therefore comparative — a different effect on sperm output than exogenous androgen — rather than a statement that one approach outperformed the other on every endpoint.

Sperm concentration and fertility-related outcomes

Spermatogenesis is the domain where enclomiphene is most often discussed, because suppression of sperm production is a recognised consequence of exogenous testosterone. The 2014 randomised phase II trial reported prevention of oligospermia in the enclomiphene arms relative to topical testosterone (PMID 25044085), and a 2019 review examined the proposition that enclomiphene citrate maintains fertility in men with secondary hypogonadism (PMID 31063005). A 2025 review of innovations in replacement and stimulatory therapies placed enclomiphene within the broader category of approaches intended to preserve spermatogenesis during treatment of testosterone deficiency (PMID 41522318).

A 2023 retrospective study compared clomiphene citrate with enclomiphene citrate for male infertility treatment (PMID 37546076). Retrospective design is a meaningful limitation: patients were not randomly assigned, and prescribing choices may have tracked baseline differences. Readers evaluating fertility-domain claims should note the distinction between semen parameters measured in a trial and pregnancy or live-birth outcomes, which the sources summarised here did not establish as a primary randomised endpoint (PMID 41066380).

Enclomiphene compared with clomiphene citrate

Clomiphene citrate is a mixture of isomers; enclomiphene is the trans-isomer isolated from it (PMID 19204885). Whether separating the isomer produced a measurable clinical difference has been examined directly. A 2024 review assessed safety and efficacy of enclomiphene and clomiphene for hypogonadal men (PMID 39434750), and a 2025 systematic review and meta-analysis of randomised controlled trials pooled trials of clomiphene or enclomiphene citrate for male hypogonadism (PMID 41066380). The 2023 retrospective comparison looked at the same question in an infertility population (PMID 37546076). Where a marketing claim asserts a clear superiority of one isomer over the mixture, the appropriate check is whether a head-to-head randomised trial reported that difference, not whether a mechanistic argument makes it plausible.

Symptom domains: libido, energy and mood

Hormone concentrations are surrogate endpoints. What people usually mean by "benefit" is symptom change. The sources summarised here addressed symptom outcomes less thoroughly than biochemical ones. A 2022 evidence-based review asked whether selective estrogen receptor modulators are safe and effective for hypogonadism in men and framed the answer in terms of the strength of available evidence (PMID 35259334), and the 2025 meta-analysis of randomised controlled trials represents the most recent attempt to pool outcomes across trials in this population (PMID 41066380). Readers should treat symptom-level claims — sharper libido, better mood, more energy — as less well supported than the hormonal findings, because they were measured less consistently and with more subjective instruments.

Outcomes frequently asked about but thinly studied

Several outcomes commonly attached to enclomiphene do not have matching evidence in the verified literature summarised on this page. Stating that plainly is more useful than extrapolating.

• Body composition, lean mass and fat loss: not reported as a primary endpoint in the trials and reviews cited here, including the 2025 pooled analysis of randomised controlled trials (PMID 41066380).
• Bone mineral density: not established as an enclomiphene endpoint in the sources summarised here (PMID 39434750).
• Cardiovascular or long-term mortality outcomes: the trials described above were short, and the 2016 pharmacotherapy review discussed the compound in the context of secondary male hypogonadism rather than long-term hard outcomes (PMID 27337642).
• Athletic performance or use in men with normal testosterone: the studied population throughout was men with low testosterone and, specifically, secondary hypogonadism (PMID 31063005).
• Restoration of testicular function after damage: a 2020 review discussed Leydig stem cells as a direction for future hypogonadism therapies, which is separate from what enclomiphene trials measured (PMID 33003069).

Adverse Events: What Studies Report

Safety was assessed at review and meta-analysis level in the sources summarised here. A 2024 review evaluated safety as well as efficacy of enclomiphene and clomiphene for hypogonadal men (PMID 39434750), and a 2025 systematic review and meta-analysis of randomised controlled trials covered clomiphene or enclomiphene citrate in male hypogonadism (PMID 41066380). A 2022 review posed safety and effectiveness of SERMs in men as its explicit question (PMID 35259334).

Two structural limitations run through the adverse-event picture. First, trial durations in this literature were short relative to the duration of real-world hormone treatment, so late or cumulative effects were not captured by the randomised phase II work (PMID 25044085). Second, enrolled populations were selected — men with secondary hypogonadism and relatively few competing conditions — so event rates observed there do not transfer automatically to broader or older populations (PMID 27337642). Questions about personal risk belong with a treating physician who can see the full clinical picture.

How strong is the evidence overall?

The strongest element is biochemical and comes from randomised work: testosterone rose, and in the 2014 phase II trial sperm concentration was reported to be preserved relative to topical testosterone (PMID 25044085). The next tier is pharmacodynamic and comparative data in men with secondary hypogonadism (PMID 23875626). Narrative reviews then interpret those findings for clinical audiences (PMID 31063005, PMID 41522318), and a 2025 systematic review and meta-analysis attempts to quantify pooled effects across randomised trials of clomiphene or enclomiphene (PMID 41066380).

What is missing is just as informative: large, long-duration randomised trials with symptom and patient-important endpoints, and head-to-head data strong enough to settle isomer-versus-mixture debates beyond what the 2024 review and the 2023 retrospective comparison could address (PMID 39434750, PMID 37546076). Reading any "benefits" list against that gap is the most reliable way to judge it.

Reading a benefit claim critically

1. Identify the population. Nearly all of this work was done in men with secondary hypogonadism, not in men with normal baseline testosterone (PMID 31063005).
2. Identify the endpoint. A rise in a laboratory value is not the same as a change in how a person feels; the 2022 SERM review framed effectiveness in exactly those evidence-grading terms (PMID 35259334).
3. Identify the comparator. Several enclomiphene findings are comparative against topical testosterone rather than placebo (PMID 23530575).
4. Identify the design. Randomised beats retrospective; the 2023 infertility comparison was retrospective (PMID 37546076).

References

• Safety and efficacy of enclomiphene and clomiphene for hypogonadal men (Translational Andrology and Urology, 2024)
• Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men (IDrugs, 2009)
• Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials (Archives of Endocrinology and Metabolism, 2025)
• Leydig stem cells and future therapies for hypogonadism (Current Opinion in Endocrinology, Diabetes, and Obesity, 2020)
• Enclomiphene citrate for the treatment of secondary male hypogonadism (Expert Opinion on Pharmacotherapy, 2016)
• Are SERMs safe and effective for the treatment of hypogonadism in men? (The Journal of Family Practice, 2022)
• Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism (Expert Review of Endocrinology & Metabolism, 2019)
• Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective Study (Cureus, 2023)
• Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel (The Journal of Sexual Medicine, 2013)
• Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics (BJU International, 2013)
• Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone (Fertility and Sterility, 2014)
• Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies (Translational Andrology and Urology, 2025)